SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+18.01%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.51B
AUM Growth
+$1.51B
(+2.7%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-7.12%
Top 10 Holdings %
Top 10 Hldgs %
65.29%
Holding
64
New
13
Increased
8
Reduced
13
Closed
14
Top Buys
| 1 |
AstraZeneca
AZN
|
$121M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$51.1M |
| 3 |
Idexx Laboratories
IDXX
|
$35.5M |
| 4 |
Exelixis
EXEL
|
$33.1M |
| 5 |
Boston Scientific
BSX
|
$32.9M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$85M |
| 2 |
Eli Lilly
LLY
|
$47.1M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$44.6M |
| 4 |
Biogen
BIIB
|
$36.9M |
| 5 |
Merck
MRK
|
$36.2M |
Sector Composition
| 1 | Healthcare | 99.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $300M | 19.62% | 1,381,149 -391,975 | -22% | -$85M |
|
2
Natera
NTRA
$23.1B
| $151M | 9.88% | 3,100,560 | – | – |
|
|
3
AstraZeneca
AZN
$248B
| $121M | 7.96% | +1,697,517 | New | +$121M |
|
4
Intuitive Surgical
ISRG
$170B
| $68.8M | 4.51% | 201,182 +51,593 | +34% | +$17.6M |
|
5
Ascendis Pharma
ASND
$11.8B
| $67.3M | 4.41% | 754,032 | – | – |
|
|
JBIO
6
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $64.5M | 4.22% | 3,758,686 | – | – |
|
|
7
Merck
MRK
$210B
| $60.9M | 3.99% | 527,373 -314,149 | -37% | -$36.2M |
|
8
Vera Therapeutics
VERA
$1.38B
| $55.6M | 3.64% | 3,467,156 | – | – |
|
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $51.1M | 3.35% | +145,300 | New | +$51.1M |
|
|
10
Exelixis
EXEL
$10.1B
| $48.9M | 3.21% | 2,560,738 +1,729,495 | +208% | +$33.1M |
|
11
DexCom
DXCM
$29.5B
| $47.6M | 3.12% | 370,720 +113,493 | +44% | +$14.6M |
|
|
12
Idexx Laboratories
IDXX
$51.8B
| $35.5M | 2.32% | +70,674 | New | +$35.5M |
|
13
Immatics
IMTX
$619M
| $35.1M | 2.3% | 3,041,487 -91,207 | -3% | -$1.05M |
|
14
Syndax Pharmaceuticals
SNDX
$1.41B
| $33.1M | 2.17% | 1,582,291 +506,867 | +47% | +$10.6M |
|
|
15
Boston Scientific
BSX
$156B
| $32.9M | 2.16% | +608,861 | New | +$32.9M |
|
|
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $32.9M | 2.15% | 322,471 -305,212 | -49% | -$31.1M |
|
17
Cytokinetics
CYTK
$4.23B
| $27.5M | 1.8% | 843,228 +489,432 | +138% | +$16M |
|
|
INBX
18
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $25.9M | 1.7% | 998,283 -246,205 | -20% | -$6.39M |
|
19
Zentalis Pharmaceuticals
ZNTL
$122M
| $23.4M | 1.53% | 828,005 -611,057 | -42% | -$17.2M |
|
|
INZY
20
DELISTED
Inozyme Pharma
INZY
| $20.4M | 1.33% | 3,655,308 | – | – |
|
21
Geron
GERN
$893M
| $17.4M | 1.14% | 5,429,155 -2,845,737 | -34% | -$9.13M |
|
22
Baxter International
BAX
$12.7B
| $16.5M | 1.08% | +362,200 | New | +$16.5M |
|
23
IDEAYA Biosciences
IDYA
$2.15B
| $15.6M | 1.02% | 664,746 +211,597 | +47% | +$4.97M |
|
|
IMGN
24
DELISTED
Immunogen Inc
IMGN
| $15.6M | 1.02% | 827,318 -97,214 | -11% | -$1.83M |
|
25
argenx
ARGX
$43.6B
| $15.6M | 1.02% | +39,921 | New | +$15.6M |
|